NCT01437228

Brief Summary

Cesarean delivery rates are increasing in Turkey and a major component of this increase is cesarean on demand. Although data on the rate of cesarean delivery in Turkey is limited, a national study reported a rate of 23.8%. Infectious morbidity, consisting primarily of endomyometritis and wound infection, remains a leading cause of postoperative complications. Estimates of postcesarean infection rates range from 7% to 20%, depending on demographic and obstetric variables. Infection following cesarean delivery results in not only increased hospital stay but also increases the cost of care. Strategies to minimize postoperative infectious and other morbidities have included modifications of surgical technique, changing of gloves, methods of placental delivery, cervical dilatation during cesarean delivery, and altering the uterine position during repair of the uterine incision. Despite these interventions, endometritis is still major problem after cesarean delivery. Endometritis appears to result from ascending vaginal flora bacteria, with anaerobes playing an important role. The microbes endogenous to the vagina change throughout the course of pregnancy and parturition. Larsen and Galask noted that anaerobic species located in the vagina increase dramatically by the third postpartum day. In many cases, the surgeon's hand, reaching below the infant's head or presenting part, is in direct contact with the vagina. Vaginal bacterial flora have been cultured from the delivering surgeon's glove in 79% (95% confidence interval \[CI\] 58%, 100%) of cesareans that follow labor. In these cases, vaginal flora are delivered directly to the uterus, abdominal cavity, and the abdominal incision. Vaginal preparation has been shown to decrease the quantitative load of vaginal microorganisms as well as to remove certain species of bacteria.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
668

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Oct 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2011

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2011

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 20, 2011

Completed
Last Updated

November 17, 2011

Status Verified

November 1, 2011

Enrollment Period

5 months

First QC Date

September 6, 2011

Last Update Submit

November 16, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • rate of postpartum endometritis

    Endometritis was defined here as body temperature greater than 38.5C with concomitant foul-smelling discharge or abnormally tender uterus on bimanual examination

    6 weeks

Secondary Outcomes (1)

  • morbidity

    two days

Study Arms (2)

povidone iodine

OTHER

30-second vaginal scrub with povidone- iodine solution.

Drug: povidone- iodine solution.

CONTROL

PLACEBO COMPARATOR
Drug: placebo

Interventions

%10 Polivinilpirolidon iyot (Polividon- iyot

Also known as: BATTICON Solüsyon. Adeka
povidone iodine

NO İNTERVENTİON

Also known as: NO İNTERVENTİON
CONTROL

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Women older than 38 weeks estimated gestational age and required cesarean section.

You may not qualify if:

  • Highly emergent cesarean
  • Allergy to povidone iodine
  • Chorioamnionitis on admission
  • Fever on admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sisli Etfal Hospital

Istanbul, Sisli, 32377, Turkey (Türkiye)

Location

Related Publications (1)

  • Haas DM, Morgan S, Contreras K, Kimball S. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. Cochrane Database Syst Rev. 2020 Apr 26;4(4):CD007892. doi: 10.1002/14651858.CD007892.pub7.

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mardin Women and Children Hospital

Study Record Dates

First Submitted

September 6, 2011

First Posted

September 20, 2011

Study Start

October 1, 2010

Primary Completion

March 1, 2011

Study Completion

April 1, 2011

Last Updated

November 17, 2011

Record last verified: 2011-11

Locations